- Home
- WSBF vs DRUG Comparison
WSBF vs DRUG Comparison
Compare WSBF & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- DRUG
- Stock Information
- Founded
- WSBF 1921
- DRUG 2019
- Country
- WSBF United States
- DRUG United States
- Employees
- WSBF N/A
- DRUG N/A
- Industry
- WSBF Savings Institutions
- DRUG Pharmaceuticals and Biotechnology
- Sector
- WSBF Finance
- DRUG Health Care
- Exchange
- WSBF Nasdaq
- DRUG Nasdaq
- Market Cap
- WSBF 240.7M
- DRUG 233.2M
- IPO Year
- WSBF N/A
- DRUG N/A
- Fundamental
- Price
- WSBF $12.92
- DRUG $25.95
- Analyst Decision
- WSBF
- DRUG Strong Buy
- Analyst Count
- WSBF 0
- DRUG 6
- Target Price
- WSBF N/A
- DRUG $83.25
- AVG Volume (30 Days)
- WSBF 49.7K
- DRUG 29.2K
- Earning Date
- WSBF 07-24-2025
- DRUG 05-15-2025
- Dividend Yield
- WSBF 4.63%
- DRUG N/A
- EPS Growth
- WSBF 95.86
- DRUG N/A
- EPS
- WSBF 1.02
- DRUG N/A
- Revenue
- WSBF $133,551,000.00
- DRUG N/A
- Revenue This Year
- WSBF N/A
- DRUG N/A
- Revenue Next Year
- WSBF N/A
- DRUG N/A
- P/E Ratio
- WSBF $12.70
- DRUG N/A
- Revenue Growth
- WSBF 1.81
- DRUG N/A
- 52 Week Low
- WSBF $11.61
- DRUG $0.93
- 52 Week High
- WSBF $16.86
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- WSBF 56.87
- DRUG 30.05
- Support Level
- WSBF $12.49
- DRUG $26.30
- Resistance Level
- WSBF $12.90
- DRUG $31.20
- Average True Range (ATR)
- WSBF 0.26
- DRUG 2.50
- MACD
- WSBF 0.04
- DRUG -0.55
- Stochastic Oscillator
- WSBF 63.53
- DRUG 5.59
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.